Trial reportToxins2023
Use of Botulinum Toxin as a Treatment of Hemiplegic Shoulder Pain Syndrome: A Randomized Trial.
Trial report in Toxins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Ultrasound-guided botulinum toxin type A for shoulder pain: a meta-analysis of randomized controlled trials.BMC musculoskeletal disorders · 2026Pooled it
- Efficacy of injection therapies in reducing hemiplegic shoulder pain: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Trial
- Temporal trajectory and predictors of hemiplegic shoulder pain after stroke: a 12-month longitudinal clinical-ultrasound study.European journal of physical and rehabilitation medicine · 2026Observational
- Benefits of Incobotulinumtoxin A in Pain, Spasticity and Functionality-A 5 Years Review.Toxins · 2026Article
- Injectable Therapies for Orofacial Myofascial Pain: A Rapid Review of Randomized Controlled Trials.Journal of clinical medicine · 2026Review
- A comparison of honeybee and scorpion venoms as anticancer agents against three different cancer cell lines: lung, colon, and breast cancer.Frontiers in toxicology · 2026Article
- Alterations in proximal shoulder muscles in stroke-related pain: a myotonometric study.Irish journal of medical science · 2025Observational
- Clinical and Ultrasound Evaluation of Hemiplegic Shoulder Pain in Stroke Patients: A Longitudinal Observational Study Starting in the First Hours After Stroke.Medicina (Kaunas, Lithuania) · 2025Observational
- ORTHOPAEDIC MANUAL PHYSICAL THERAPY FOR POST-STROKE SHOULDER PAIN: TWO CASE REPORTS INCLUDING CLINICAL ASSESSMENTS AND PARTICIPANTS' EXPERIENCES.Journal of rehabilitation medicine. Clinical communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe primary objective of this paper is to assess whether the use of 200 units of abobotulinum in the pectoralis major and subscapularis muscles modifies the pain complaint assessed using the visual analog scale in subjects with shoulder pain after the onset of spastic hemiplegia due to cerebrovascular disease when compared to the application of a placebo to the same muscles.
designA prospective, double-blind, randomized, and placebo-controlled clinical trial study in two different rehabilitation centers.
settingTwo distinct outpatient neurological rehabilitation services.
participantsPatients older than 18 years who were included presented upper limb spasticity resulting from ischemic or hemorrhagic stroke and a diagnosis of Painful Hemiplegic Shoulder Syndrome (PHSS) that was independent of motor dominance.
interventionsPatients were divided into two groups, one of them underwent the application of botulinum toxin (TXB-A) in the pectoralis major and subscapularis muscles, at a total dose of 400 U.
main outcome measurePatients were assessed for a change in pain using the Visual Analog Scale (VAS) for at least 13 mm.
resultsAn improvement in pain and spasticity levels in both groups, more intense in the toxin group, but without statistical significance. The comparison between the groups showed a reduction in pain by VAS (
conclusionsThe use of botulinum toxin in the subscapularis and pectoralis major muscles resulted in a reduction in shoulder pain in spastic hemiplegic patients without statistical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.